Inhibition of Wnt signalling and breast tumour growth by the multi-purpose drug suramin through suppression of heterotrimeric G proteins and Wnt endocytosis.

Détails

Ressource 1Télécharger: 26604320AM.pdf (3007.75 [Ko])
Etat: Public
Version: Author's accepted manuscript
ID Serval
serval:BIB_B64BFFC5D22C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Inhibition of Wnt signalling and breast tumour growth by the multi-purpose drug suramin through suppression of heterotrimeric G proteins and Wnt endocytosis.
Périodique
Biochemical Journal
Auteur(s)
Koval A., Ahmed K., Katanaev V.L.
ISSN
1470-8728 (Electronic)
ISSN-L
0264-6021
Statut éditorial
Publié
Date de publication
2016
Peer-reviewed
Oui
Volume
473
Numéro
4
Pages
371-381
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
Overactivation of the Wnt signalling pathway underlies oncogenic transformation and proliferation in many cancers, including the triple-negative breast cancer (TNBC), the deadliest form of tumour in the breast, taking about a quarter of a million lives annually worldwide. No clinically approved targeted therapies attacking Wnt signalling currently exist. Repositioning of approved drugs is a promising approach in drug discovery. In the present study we show that a multi-purpose drug suramin inhibits Wnt signalling and proliferation of TNBC cells in vitro and in mouse models, inhibiting a component in the upper levels of the pathway. Through a set of investigations we identify heterotrimeric G proteins and regulation of Wnt endocytosis as the likely target of suramin in this pathway. G protein-dependent endocytosis of plasma membrane-located components of the Wnt pathway was previously shown to be important for amplification of the signal in this cascade. Our data identify endocytic regulation within Wnt signalling as a promising target for anti-Wnt and anti-cancer drug discovery. Suramin, as the first example of such drug or its analogues might pave the way for the appearance of first-in-class targeted therapies against TNBC and other Wnt-dependent cancers.
Mots-clé
Animals, Antineoplastic Agents/pharmacology, Breast Neoplasms/metabolism, Breast Neoplasms/pathology, Cell Proliferation/drug effects, Endocytosis/drug effects, Female, HEK293 Cells, HeLa Cells, Heterotrimeric GTP-Binding Proteins/metabolism, Humans, Mice, Mice, Inbred NOD, Mice, SCID, Signal Transduction/drug effects, Suramin/pharmacology, Wnt3A Protein/metabolism, Xenograft Model Antitumor Assays
Pubmed
Web of science
Open Access
Oui
Création de la notice
28/05/2016 9:42
Dernière modification de la notice
20/08/2019 15:24
Données d'usage